SIG SAUER Celebrates Major Milestone: 100 Million Round Annual 6.8mm Ammunition Capacity
American Manufacturing Creates Economic Growth for Arkansas JACKSONVILLE, Ark., July 1, 2025…
New Global Aesthetics Report: A Shift Towards Facial Surgery Globally as Eyelid Ranks Top Procedure
Aesthetic Procedures Close to 38 Million in 2024. MOUNT ROYAL, N.J., June 20,…
ReversingLabs Named to Inc.s 2025 Best Workplaces List
CAMBRIDGE, Mass., June 17, 2025 (GLOBE NEWSWIRE) -- ReversingLabs, the trusted name…
Circle Pharma Receives FDA Orphan Drug Designation for CID-078 for the Treatment of Small Cell Lung Cancer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--#Biotech--Circle Pharma, a clinical-stage biopharmaceutical company advancing macrocycle…
Investigational combination of first-in-class bispecific antibodies TALVEY (talquetamab) and TECVAYLI (teclistamab) shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease
Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9…
XRP payment volume surged 1,300% in a single day, and the XRP Mining platform attracted thousands of investors in a single day
Houston, TX, June 13, 2025 (GLOBE NEWSWIRE) -- Against the backdrop of…
Dupixent (dupilumab) Data at Revolutionizing Atopic Dermatitis (RAD) Conference Reinforce Use in Atopic Dermatitis Patients with Skin of Color
Atopic dermatitis is a chronic disease that disproportionately impacts communities of color…
Bin There Dump That Named to Entrepreneur Magazines Franchise 500 Hall of Fame
WILMINGTON, Del.--(BUSINESS WIRE)--Bin There Dump That, North America’s leading residential-friendly dumpster rental…
Persistent Achieves Top Rankings for the Second Year in a Row in Extel’s Asia Executive Team Survey
Recognized under multiple categories, including Best CEO, Company Board of Directors, Overall…
Actuate Therapeutics Presents Topline Elraglusib Phase 2 Data at ASCO 2025 Annual Meeting: Trial Meets Primary Endpoint of Median Overall Survival and Doubles 1-Year Survival in First-Line Treatment of Metastatic Pancreatic Cancer
Phase 2 (Actuate-1801 Part 3B) trial meets primary endpoint and demonstrates a…